Rexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at the 2016 Targeted Anticancer Therapeutics Congress Mar 24, 2016
Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin® Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma Feb 8, 2016
Rexahn Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 Feb 1, 2016
Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations at the 2016 Gastrointestinal Cancers Symposium Jan 25, 2016
New Preclinical Data for Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition Jan 12, 2016
Rexahn Pharmaceuticals’ Archexin® Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study Jan 11, 2016
Rexahn Pharmaceuticals Announces New Data for Supinoxin™ Showing Potent Tumor Growth Inhibition Dec 14, 2015